LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

A similar study in Gastro Hep Advances found higher odds of GERD and gastroparesis among patients with type 2 diabetes taking GLP-1 agonists versus SGLT-2 inhibitors, but lower odds of acute ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Eli Lilly’s Omvoh ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

As pressure builds around drug pricing and access, US trade group PhRMA is pushing back against criticism of pharmaceutical patents. In a recent blog post, the organization argued that intellectual ...